Dupilumab Significantly Improves Atopic Dermatitis in Children Aged ≥6 to <12 years: Results From Phase 3 Trial (LIBERTY AD PEDS)

Amy S. Paller1, Elaine C. Siegfried2,3, Melinda Gooderham4,5, Lisa A. Beck6, Mark Boguniewicz7,8, Lawrence Sher9, Jamie Weisman10, Heribert W. Staudinger11, Xian Sun12, Brad Shumel12

1Northwestern University Feinberg School of Medicine, Chicago, IL, USA; 2Saint Louis University, St. Louis, MO, USA; 3Cardinal Glennon Children’s Hospital, St. Louis, MO, USA; 4SKiN Centre for Dermatology, Peterborough, ON, Canada; 5Queen’s University, Kingston, ON, Canada; 6University of Rochester Medical Center, Rochester, NY, USA; 7National Jewish Health, Denver, CO, USA; 8University of Colorado School of Medicine, Denver, CO, USA; 9Peninsula Research Associates, Rolling Hills Estates, CA, USA; 10Advanced Medical Research, PC, Atlanta, GA, USA; 11Sanofi, Cambridge, MA, USA; 12Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA;

Background: Dupilumab is approved in the USA for subcutaneous administration every 2 weeks (q2w) for the treatment of patients aged ≥12 years with moderate-to-severe atopic dermatitis (AD) inadequately controlled with topical prescription therapies or when those therapies are not advisable. We present dupilumab efficacy and safety data in children aged ≥6 to <12 years with severe AD.

Methods: In this double-blind trial (NCT03345914), children aged ≥6 to <12 years (minimum weight 15kg) with severe AD (Investigator’s Global Assessment [IGA] score=4) were randomized 1:1:1 to subcutaneous dupilumab q2w (100mg if baseline weight <30kg, 200mg if ≥30kg), every 4 weeks (q4w, 300mg regardless of weight), or placebo for 16 weeks. From Day –14, all patients initiated standardized treatment with medium-potency topical corticosteroids (TCS).

Results: 367 patients were randomized (q2w/q4w/placebo groups, n=122/n=122/n=123). At Week 16, 29.5%/32.8%/11.4% of patients receiving q2w/q4w/placebo achieved IGA scores of 0/1 (clear/almost clear); 67.2%/69.7%/26.8% achieved ≥75% improvement from baseline in Eczema Area and Severity Index (EASI). Least squares (standard error) mean percent change in EASI and Peak Pruritus Numerical Rating Scale were –78.4(2.35)/–82.1(2.37)/–48.6(2.46) and –57.0 (2.77)/–54.6 (2.89)/–25.9(2.90), respectively (P<0.001 vs placebo for all comparisons). Serious adverse events (AEs) and AE-related treatment discontinuations were rare; injection-site reactions and conjunctivitis were more common with dupilumab than with placebo.
**Conclusion:** Dupilumab+TCS showed clinically meaningful and statistically significant improvement in AD signs and symptoms in children aged ≥6 to <12 years with severe AD and was well tolerated with no new safety signals compared with adults and adolescents.

**Acknowledgments:**
Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ClinicalTrials.gov Identifier: NCT03345914 (LIBERTY AD PEDS). Medical writing/editorial assistance provided by Ferdinando Giacco, of Excerpta Medica, funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.

**Disclosures:**
**Paller AS:** AbbVie, AnaptysBio, Eli Lilly, Galderma, Incyte, Janssen, LEO Pharma, Novartis, Regeneron Pharmaceuticals, Inc., Sanofi – investigator; AbbVie, Amgen, Asana, Dermavant, Dermira, Eli Lilly, Forte, Galderma, LEO Pharma, Matrisys Bioscience, Menlo Therapeutics, MorphoSys/Galapagos, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi – consultant. **Siegfried EC:** Dermavant, Eli Lilly, Pfizer, Regeneron Pharmaceuticals, Inc., Verrica – consultant; GSK, LEO Pharma, Novan – Data and Safety Monitoring Board; Eli Lilly, Janssen, Regeneron Pharmaceuticals, Inc., Stiefel, Verrica – Principal Investigator in clinical trials. **Gooderham M:** AbbVie, Akros, Amgen, Arcutis, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Coherus BioSciences, Dermira, Eli Lilly, Galderma, GSK, Janssen, Kyowa Kirin, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Roche, Sanofi Genzyme, Sun Pharma, UCB, Valeant – investigator, advisor, and/or speaker. **Beck LA:** Abbvie, LEO Pharma, Pfizer, Regeneron Pharmaceuticals, Inc. – investigator; AbbVie, Allakos, Arena Pharma, Astra-Zeneca, Connect Biopharma, Eli Lilly, LEO Pharma, Novan, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi, UCB and Vimalan – consultant. Pfizer, Medtronics – holds stock options. **Boguniewicz M:** Regeneron Pharmaceuticals, Inc., Sanofi – research grants, consulting, honoraria for lectures; Eli Lilly – consultant. **Sher L:** Aimmune, Optinose, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme – advisor; Regeneron Pharmaceuticals, Inc., Sanofi Genzyme – speaker fees; Aimmune, Amgen, AstraZeneca, Circassia, DBV, Galderma, GSK, Lupin, Merck, Mylan, Novartis, Novo Nordisk, Optinose, Pearl, Pfizer, Pulmagen, Roxane, Sanofi, Spirometrix, Teva, Watson, Vectura – clinical trials funding. **Weisman J:** AbbVie, Allergan, Amgen, Boehringer Ingelheim, Celgene, Dermira, Eli Lilly, Galderma, GSK, Janssen, LEO Pharma, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., UCB – research grants; AbbVie, Eli Lilly, Janssen, Regeneron Pharmaceuticals, Inc., UCB – advisory board member or speakers bureau. **Staudinger HW:** Sanofi –
employee, may hold stock and/or stock options in the company. **Sun X, Shumel B**: Regeneron Pharmaceuticals, Inc. – employees and shareholders.